Real world experience with Emicizumab in severe haemophilia A (HA) in Senegal, West Africa

被引：0
|
作者：
Diop, Saliou [1 ]
Seck, Moussa [1 ]
Mbomboa, Safiya [1 ]
Martin, Jayson [2 ]
Toure, Sokhna Aissatou [1 ]
Senghor, Alioune Badara [3 ]
Bousso, Elimane Seydi [1 ]
Keita, Mohamed [1 ]
Diallo, Alioune Badara [1 ]
Faye, Blaise Felix [1 ]
Sy, Diariatou [1 ]
Haffar, Assad [2 ]
机构：
[1] Univ Cheikh Anta Diop, Dept Hematol, IHTC Dakar, Dakar, Senegal
[2] World Federat Hemophilia, Montreal, PQ, Canada
[3] Univ Cheikh Anta Diop, Dakar, Senegal
来源：
HAEMOPHILIA | 2022年 / 28卷
关键词：
Emicizumab; low and middle income countries; prophylaxis;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
FP-08.04 (
引用
收藏
页码：69 / 70
页数：2
相关论文
共 50 条
  • [41] EMICIZUMAB IN HAEMOPHILIA A: REAL-WORD EXPERIENCE ON THE MANAGEMENT OF MILD HEAD TRAUMA IN A COHORT OF CHILDREN WITH AND WITHOUT INHIBITORS
    Gallizio, E.
    Pollio, B.
    Ricca, I
    Linari, C.
    Ramenghi, U.
    Zanon, E.
    Albiani, R.
    HAEMOPHILIA, 2023, 29 : 52 - 53
  • [42] Real-world data for the use of emicizumab in haemophilia A patients with inhibitors - First nationwide report from Korea
    Hahn, Seung Min
    Han, Jung Woo
    Kim, Jin Seok
    Shim, Ye Jee
    Kim, Soyon
    Kim, Hugh Chul
    Park, Young Shil
    Lyu, Chuhl Joo
    HAEMOPHILIA, 2023, 29 (04) : 1163 - 1166
  • [43] Real-World Safety of Emicizumab: The First Interim Analysis of the European Haemophilia Safety Surveillance (EUHASS) Database
    Shang, Aijing
    Bienz, Nives Selak
    Gadiraju, Ravi
    Chang, Tiffany
    Kuebler, Peter
    BLOOD, 2020, 136
  • [44] Long-term analysis of real clinical practice of emicizumab treatment in patients with severe haemophilia A with and without FVIII inhibitors
    Zozulya, N.
    Dimitrieva, O.
    Yakovleva, E.
    HAEMOPHILIA, 2024, 30 : 122 - 122
  • [45] Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real-world data
    Misgav, Mudi
    Brutman-Barazani, Tami
    Budnik, Ivan
    Einat, Avishai
    Schapiro, Jonathan
    Bashari, Dalia
    Barg, Assaf A.
    Lubetsky, Aaron
    Livnat, Tami
    Kenet, Gili
    HAEMOPHILIA, 2021, 27 (02) : 253 - 260
  • [46] Patient-determined discontinuation of regular prophylaxis for severe haemophilia: the west of Scotland experience
    Mccaig, A
    Chalmers, E
    Tait, RC
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 87 - 88
  • [47] REAL-WORLD EXPERIENCE WITH EMICIZUMAB IN AN ITALIAN PAEDIATRIC COHORT: FOCUS ON PUPS AND TOLERIZED CHILDREN
    Pollio, B.
    Ricca, I
    Linari, C.
    Martinoli, C.
    Albiani, R.
    HAEMATOLOGICA, 2021, 106 (09) : 15 - 15
  • [48] REAL-WORLD DATA ON EMICIZUMAB PROPHYLAXIS IN THE MILAN COHORT: A SINGLE-CENTER EXPERIENCE
    Arcudi, S.
    Gualtierotti, R.
    Ciavarella, A.
    Marino, S.
    Siboni, S.
    Biguzzi, E.
    Boccalandro, E.
    Begnozzi, V.
    Schiavone, L.
    Novembrino, C.
    Valsecchi, C.
    Peyvandi, F.
    HAEMOPHILIA, 2022, 28 : 84 - 84
  • [49] Real world experience using emicizumab in paediatric patients: Clinical features and joint health evaluation
    Estival-Monteliu, P.
    Caballero, N.
    Benedicto, C.
    Rodriguez-Nieva, N.
    Berrueco, R.
    HAEMOPHILIA, 2024, 30 : 110 - 110
  • [50] Real world management of individuals with severe FXI deficiency and its impact on clinical outcomes: Experience from a haemophilia treatment centre
    Wu, S. Julia
    Cacciola-Price, Nicholas J.
    Goldberg, Ilene
    DeSancho, Maria T.
    HAEMOPHILIA, 2024, 30 (05) : 1164 - 1169
12345